Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

CEL-SCI Corporation (CVM)

13.99   -0.41 (-2.85%) 05-22 16:00
Open: 14.5 Pre. Close: 14.4
High: 14.72 Low: 13.75
Volume: 558,768 Market Cap: 526M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.736 - 14.856 14.856 - 14.937
Low: 13.512 - 13.638 13.638 - 13.723
Close: 13.823 - 14.021 14.021 - 14.154

Technical analysis

as of: 2020-05-24 6:46:53 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 17.62     One year: 21.02
Support: Support1: 10.37    Support2: 8.63
Resistance: Resistance1: 15.09    Resistance2: 18.00
Pivot: 14.59
Moving Average: MA(5): 14.70     MA(20): 14.97
MA(100): 12.59     MA(250): 9.56
MACD: MACD(12,26): 0.47     Signal(9): 0.66
Stochastic oscillator: %K(14,3): 35.76     %D(3): 42.70
RSI: RSI(14): 48.96
52-week: High: 18.00  Low: 3.70  Change(%): 211.6
Average Vol(K): 3-Month: 87838  10-Days: 71003

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
CVM has closed above bottom band by 33.1%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 11 May 2020
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results - Yahoo Finance

Mon, 04 May 2020
CEL-SCI's Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer - Business Wire

Mon, 04 May 2020
CEL-SCI Corp (CVM) Announces Phase 3 Study Has Reached Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer -

Fri, 08 May 2020
CVM: 298 Events Achieved - Yahoo Finance

Mon, 04 May 2020
Cel-Sci almost there with late-stage Multikine study - Seeking Alpha

Wed, 06 May 2020
Cel-Sci Corporation - Consensus Indicates Potential 10.0% Upside - DirectorsTalk Interviews

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 38
Shares Float (M) 36
% Held by Insiders 4.48
% Held by Institutions 21.78
Shares Short (K) 5,460
Shares Short P. Month (K) 5,710

Stock Financials

EPS -0.910
EPS Est This Year -0.420
EPS Est Next Year -0.290
Book Value (p.s.) 0.330
Profit Margin
Operating Margin -4677.96
Return on Assets (ttm) -51.1
Return on Equity (ttm) -477.7
Qtrly Rev. Growth 98.1
Gross Profit (p.s.) -0.324
Sales Per Share 0.014
EBITDA (p.s.) -0.613
Qtrly Earnings Growth
Operating Cash Flow (M) -17
Levered Free Cash Flow (M) -9

Stock Valuations

PE Ratio -15.37
PEG Ratio
Price to Book value 42.39
Price to Sales 1012.78
Price to Cash Flow -31.87

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 1996-08-27
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.